THE CRITICAL PATH INSTITUTE (C-PATH) NON PROFIT CORPORATION

Their core work

The Critical Path Institute (C-PATH) is a US-based non-profit that operates at the intersection of pharmaceutical industry, regulatory agencies, and academia to accelerate drug development by building pre-competitive scientific consensus. Their core work is qualifying biomarkers and standardizing clinical trial methodologies so that research findings become accepted regulatory tools — recognized by bodies like the FDA and EMA. Rather than running laboratory experiments themselves, they convene consortia of competitors who share data on shared problems, converting that pooled evidence into qualification packages and international standards. For any organization working on drug development tools or clinical trial methodology, C-PATH offers a direct channel into the regulatory acceptance process.

What they specialise in

How they've shifted over time

C-PATH entered H2020 in 2019 with a focus on drug safety biomarkers — qualifying laboratory-based translational markers that link preclinical signals to clinical outcomes. By 2021, their second project shifted toward patient-reported outcomes and clinical trial analysis standards, moving upstream from safety tools into trial design and endpoint methodology. This progression suggests a deliberate broadening from preclinical safety science into the full clinical trial quality stack — an organization expanding its regulatory toolkit to cover both what happens before and during trials.

C-PATH is moving from preclinical safety science toward clinical trial methodology and patient-centered endpoint standards, suggesting a growing role in defining how clinical evidence is generated and measured across the drug development pipeline.

How they like to work

C-PATH joins projects exclusively as a participant, never as coordinator — consistent with their role as a neutral scientific convener rather than a project driver. What is striking is the scale of their network: 61 unique partners across 17 countries from just 2 projects, which signals participation in very large multi-stakeholder IMI consortia rather than small academic collaborations. This pattern means working with C-PATH brings access to a dense pharmaceutical-regulatory network, but expect them to contribute consensus-building and regulatory pathway expertise rather than laboratory capacity.

Despite only two H2020 projects, C-PATH has collaborated with 61 unique partners across 17 countries — an exceptionally high ratio of partners-per-project that reflects their involvement in large pre-competitive consortia. Their US base combined with European project participation positions them as a transatlantic bridge between American regulatory science (FDA) and European drug development programs.

What sets them apart

C-PATH is one of the very few US non-profits with a track record in EU-funded health research, offering a direct connection to FDA regulatory processes that European partners typically lack. Unlike academic partners, they do not primarily produce scientific publications — they produce regulatory qualification packages and international standards, which is a fundamentally different and more commercially relevant output. For a consortium building a drug development tool that needs regulatory acceptance on both sides of the Atlantic, C-PATH is a rare asset.

Highlights from their portfolio

• TransBioLine
  A flagship IMI project qualifying novel translational safety biomarkers across multiple organ systems, with outputs designed for direct regulatory submission — exactly the type of work C-PATH was founded to do.
• SISAQOL-IMI
  Addresses one of clinical oncology's persistent problems — the inconsistent analysis of patient-reported outcomes across trials — by setting international standards that could reshape how endpoints are handled in cancer drug approvals.